The University of Massachusetts Amherst is supplying local hospitals and the state with key ingredients needed for COVID-19 testing.

Scientists at academic labs equipped to test for SARS-CoV-2 report that multiple barriers are preventing from them from operating at full capacity.

Super-resolution imaging identifies abnormalities in the hair-like protrusions on a cell’s surface and may help facilitate earlier detection of primary ciliary dyskinesia.

The machine can be run in doctor’s offices and other point-of-care settings to give rapid results.

Hospitals and commercial companies are testing thousands of patients for COVID-19 daily, but face reagent and supply shortages.

Current methods to detect infections of the novel coronavirus rely on identifying particular genetic sequences, but new assays are being developed to meet the growing demand for rapid answers.

More cases emerge across the country as the global death toll from COVID-19 surpasses 3,000.

Some US states are waiting for the CDC to send replacement enzymes necessary for carrying out SARS-CoV-2 assays.

The US Food and Drug Administration authorizes the distribution of the 2019-nCoV diagnostic to state health departments and other facilities.